エンザルタミドとカルシウム拮抗薬の薬物相互作用が血圧変動に及ぼす影響

• 資料種別: 記事
• タイトル: エンザルタミドとカルシウム拮抗薬の薬物相互作用が血圧変動に及ぼす影響
• 著者標目: 守田 和憲; 北岡 朋子; 佐々 扶美; 鬼木 健太郎; 猿渡 淳二; 田上 治美
• 出版年月日等: 2023-02-10
• 出版年（W3CDTF）: 2023-02-10
• タイトル（掲載誌）: 医療薬学
• 巻号年月日等（掲載誌）: 49 2
• 掲載巻: 49
• 掲載号: 2
• 掲載ページ: 59-65
• 掲載年月日（W3CDTF）: 2023-02-10
• ISSN（掲載誌）: 1346342X
• ISSN-L（掲載誌）: 1346342X
• 出版事項（掲載誌）: Japanese Society of Pharmaceutical Health Care and Sciences
• 本文の言語コード: ja
• 件名標目: drug interaction; prostate cancer; enzalutamide; hypertension; calcium channel blocker; cytochrome P450
• 対象利用者: 一般
• DOI: 10.5649/jjphcs.49.59
• 関連情報（URI）: https://www.jstage.jst.go.jp/article/jjphcs/49/2/49_59/_pdf; https://search.jamas.or.jp/link/ui/2023125957
• 参照: Effect of Comorbidity on Prostate Cancer–Specific Mortality: A Prospective Observational Study; https://cir.nii.ac.jp/crid/1360017981627205120; Abiraterone and enzalutamide had different adverse effects on the cardiovascular system: a systematic review with pairwise and network meta-analyses; https://cir.nii.ac.jp/crid/1360017982286629120; Preventive drugs in the last year of life of older adults with cancer: Is there room for deprescribing?; https://cir.nii.ac.jp/crid/1360017985268677120; Drug–drug interaction potential in men treated with enzalutamide: Mind the gap; https://cir.nii.ac.jp/crid/1360299456605245312; Increased Risk of Hypertension with Enzalutamide in Prostate Cancer: A Meta-Analysis; https://cir.nii.ac.jp/crid/1360299461080270080; Co-morbidities in a Retrospective Cohort of Prostate Cancer Patients; https://cir.nii.ac.jp/crid/1360580933694548224; Enzalutamide in Japanese patients with chemotherapy‐naïve, metastatic castration‐resistant prostate cancer: A post‐hoc analysis of the placebo‐controlled PREVAIL trial; https://cir.nii.ac.jp/crid/1360846643096760192; Impact of enzalutamide and its main metabolite <i>N</i>‐desmethyl enzalutamide on pharmacokinetically important drug metabolizing enzymes and drug transporters; https://cir.nii.ac.jp/crid/1360855569801777792; Consequences of an Early PSA Response to Enzalutamide Treatment for Japanese Patients with Metastatic Castration-resistant Prostate Cancer; https://cir.nii.ac.jp/crid/1361137043710025344; Cytochrome P450 3A Induction Predicts P‐glycoprotein Induction; Part 1: Establishing Induction Relationships Using Ascending Dose Rifampin; https://cir.nii.ac.jp/crid/1361418520570922368; Increased Survival with Enzalutamide in Prostate Cancer after Chemotherapy; https://cir.nii.ac.jp/crid/1361981468726289408; ARCHES: A Randomized, Phase III Study of Androgen Deprivation Therapy With Enzalutamide or Placebo in Men With Metastatic Hormone-Sensitive Prostate Cancer; https://cir.nii.ac.jp/crid/1362262945038791808; Evaluation of a Pharmacist-Led Medication Assessment Used to Identify Prevalence of and Associations With Polypharmacy and Potentially Inappropriate Medication Use Among Ambulatory Senior Adults With Cancer; https://cir.nii.ac.jp/crid/1363107368641602816; Development of a Second-Generation Antiandrogen for Treatment of Advanced Prostate Cancer; https://cir.nii.ac.jp/crid/1363107369007906816; Pharmacokinetic Drug Interaction Studies with Enzalutamide; https://cir.nii.ac.jp/crid/1363951796102461952; General Framework for the Prediction of Oral Drug Interactions Caused by CYP3A4 Induction from In Vivo Information; https://cir.nii.ac.jp/crid/1363951796246792064; Enzalutamide in Metastatic Prostate Cancer before Chemotherapy; https://cir.nii.ac.jp/crid/1364233271212775552
• 連携機関・データベース: 国立情報学研究所 : CiNii Research
• 提供元機関・データベース: Japan Link Center; https://japanlinkcenter.org/top; Crossref; https://www.crossref.org

• 要約等: <p>Enzalutamide, a potent androgen-receptor inhibitor, is known to induce drug-metabolizing enzymes including cytochrome P450 (CYP) 3A4, 2C9, and 2C19...